Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Additionally we are shipping Glypican 3 Kits (57) and Glypican 3 Proteins (13) and many more products for this protein.
Showing 10 out of 280 products:
Human Polyclonal Glypican 3 Primary Antibody for EIA, WB - ABIN952555
Lai, Oseini, Moser, Yu, Elsawa, Hu, Nakamura, Han, Aderca, Isomoto, Garrity-Park, Shire, Li, Sanderson, Adjei, Fernandez-Zapico, Roberts: The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation. in Hepatology (Baltimore, Md.) 2010
Show all 5 references for ABIN952555
Human Polyclonal Glypican 3 Primary Antibody for EIA, IF - ABIN1449428
Nakatsura, Kageshita, Ito, Wakamatsu, Monji, Ikuta, Senju, Ono, Nishimura: Identification of glypican-3 as a novel tumor marker for melanoma. in Clinical cancer research : an official journal of the American Association for Cancer Research 2004
Show all 5 references for ABIN1449428
Human Polyclonal Glypican 3 Primary Antibody for IF, WB - ABIN652202
Boily, Saikali, Sinnett: Methylation analysis of the glypican 3 gene in embryonal tumours. in British journal of cancer 2004
Show all 3 references for ABIN652202
Human Polyclonal Glypican 3 Primary Antibody for IF, WB - ABIN390319
Wichert, Stege, Midorikawa, Holm, Lage: Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells. in Oncogene 2004
Show all 3 references for ABIN390319
Human Monoclonal Glypican 3 Primary Antibody for ICC, FACS - ABIN969523
Zittermann, Capurro, Shi, Filmus: Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. in International journal of cancer. Journal international du cancer 2010
Show all 2 references for ABIN969523
Human Monoclonal Glypican 3 Primary Antibody for EIA, IF - ABIN1107403
Takai, Ashihara, Ishiguro, Terashima, Watanabe, Kato, Suzuki: Involvement of glypican-3 in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma. in Cancer biology & therapy 2010
Show all 2 references for ABIN1107403
Cow (Bovine) Polyclonal Glypican 3 Primary Antibody for WB - ABIN2780199
Bhave, Mars, Donthamsetty, Zhang, Tan, Luo, Bowen, Michalopoulos: Regulation of liver growth by glypican 3, CD81, hedgehog, and Hhex. in The American journal of pathology 2013
Show all 2 references for ABIN2780199
Glypican 3 expression showed a significant difference between endometrioid endometrial carcinoma and serous endometrial carcinoma, and it was significantly correlated with tumor grade, stage and myometrial invasion
Data show that notum (show NOTUM Antibodies) and glypican-1 (show GPC1 Antibodies) and glypican-3 gene expression during colorectal cancer (CRC (show CALR Antibodies)) development and present evidence to suggest them as potential new biomarkers of CRC (show CALR Antibodies) pathogenesis.
GPC3 expression was measured in hepatocellular carcinoma at different stages and correlated with prognosis. CK19 (show KRT19 Antibodies)+/GPC3+ HCC (show FAM126A Antibodies) has the highest risk of intrahepatic metastasis, microvascular invasion, regional lymph node involvement, and distant metastasis.
Review: Glypican-3 is a highly specific biomarker for the diagnosis of hepatocellular carcinoma and a promising therapeutic target.
In South Korean hepatocellular carcinoma patients, GPC3 expression was more frequent in hepatocellular carcinoma with aggressive features, but it was not an independent prognostic biomarker.
In this meta-analysis, GPC3 was found to be acceptable as a serum marker for the diagnosis of hepatocellular carcinoma.
GPC3 may be a candidate marker for detecting lung squamous cell carcinoma.
study suggests that GPC3 is involved in HCC (show FAM126A Antibodies) cell migration and motility through HS chain-mediated cooperation with the HGF (show HGF Antibodies)/Met pathway, showing how HS targeting has potential therapeutic implications for liver cancer
potential role of GPC3 in urothelial carcinogenesis warrants further investigation, especially the potential use of Glypican-3 for therapeutic and diagnostic purposes
Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of ovarian cancer.
Data show that notum (show NOTUM Antibodies) and glypican-1 (show GPC1 Antibodies) and glypican-3 gene expression during colorectal cancer (CRC (show SCRIB Antibodies)) development and present evidence to suggest them as potential new biomarkers of CRC (show SCRIB Antibodies) pathogenesis.
Coupling of pGPC3 to liposomes was essential for effective priming of GPC3-specific CTLs.
The expression of GPC-3 was altered by DEN treatment.
Data suggest that GPC3 down-regulates hepatocyte proliferation by binding to hedgehog (show SHH Antibodies) (HH) and down-regulating the HH signaling pathway and binding with CD81 (show CD81 Antibodies), thus making it unavailable to bind to Hhex (show HHEX Antibodies) and causing its nuclear translocation.
Finding represents a rare four layer genomic overlap consisting of growth associated quantitative trait locus (QTL), body mass associated Gpc3 gene, highly conserved miRNA gene and mature miRNA seed SNP identified in the lean mouse.
Hepatocyte overexpression of GPC3 suppresses hepatocyte proliferation and liver regeneration and alters gene expression profiles.
glypican-3 is involved in the recruitment of M2-polarized tumor-associated macrophages in hepatocellular carcinoma
GPC3 inhibits the PI3K/Akt (show AKT1 Antibodies) anti-apoptotic pathway while it stimulates the p38MAPK (show MAPK14 Antibodies) stress-activated one in murine mammary adenocarcinoma LM3 cells
Gpc3 function in development of Simpson-Golabi-Behmel syndrome is IGF-independent
GPC3 knockout mice exhibit alterations in the Wnt (show WNT2 Antibodies) signaling pathway, which is also associated with the regulation of cell proliferation
Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. The protein encoded by this gene can bind to and inhibit the dipeptidyl peptidase activity of CD26, and it can induce apoptosis in certain cell types. Deletion mutations in this gene are associated with Simpson-Golabi-Behmel syndrome, also known as Simpson dysmorphia syndrome. Alternative splicing results in multiple transcript variants.
, glypican proteoglycan 3
, heparan sulphate proteoglycan
, intestinal protein OCI-5
, secreted glypican-3
, defective in Simpson-Golabi-Behmel overgrowth syndrome
, proteoglycan GPC3
, Intestinal protein OCI-5